BioMark Diagnostics Inc C.BUX

Alternate Symbol(s): BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

CSE:BUX - Post by User

BioMark Diagnostics Inc

Bullboard Posts

Comment by sailtakeron Oct 29, 2015 2:33pm

85 Views

Post# 24239975

RE:anonymous

Actually anonymous is the 1 that sold it heavily down
to this level (likely short), and now he is starting to cover.
Those who sell to him are aiding his game, don't sell and
he will have to buy higher than here. Just don't sell to him.
This stock is worth much more....

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023